Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Effectiveness of CAR-T in Relapsed/Refractory Hodgkin's Lymphoma
NCT04665063Phase 2Recruiting
- Sponsor
- Senlang Bio
- Start
- Oct 2020
- Primary completion
- Oct 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD30 CAR-T (Hebei Senlang) in Hodgkin lymphoma (HL), sponsored by Senlang Bio. Started Oct 2020; status: recruiting.
02
Drugs
CD30 CAR-T (Hebei Senlang)
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT04665063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04665063.